DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Pediatrics
Current Location:
> This Story

Log in or Register to rate this News Story
Forward Printable StoryPrint Comment




More Magazine Features

Installing and removing imaging equipment is no small task Expert insights on how project management is evolving

Informatics, standardization and the next phase for enterprise imaging Life after silos is coming into focus

Assessing the state of Alzheimer’s imaging The battle against neuro-degenerative disease wages on

Patient monitors help hospitals do more with less The latest monitors focus on workflow, EHR integration and remote capabilities

Tips for creating better collaboration between HTM and IT Streamlining these increasingly complex partnerships

See All Magazine Features  

Molecular Imaging Homepage

US suppliers to join the Mo-99 market, high-energy materials gaining traction Radiopharmaceutical supply chain update

Navigating the molecular imaging market Purchasing insights from the experts at MD Buyline

Assessing the state of Alzheimer’s imaging The battle against neuro-degenerative disease wages on

Absolute Imaging Solutions acquires Northeast Electronics Facilitates push into East Coast market

Eden Radioisotopes scores funding for isotope reactor production Will primarily produce Mo-99

SHINE secures rights to new method for Lutetium-177 production Generate Lu-177 at greater speed and scale

FDA gives green light to new United Imaging PET/MR scanner The uPMR 790 HD TOF performs total-body scans within 20 minutes

FDA reminder for properly eluting rubidium 82 generators prompted by 'recent incidents' Using incorrect solutions puts patients at risk

Generating higher quality PET images 100x faster at MSK 'No one has done PET imaging in this way before'

Louisiana getting $14 million Center for Molecular Imaging and Therapy Increasing research opportunities, collaboration and radiopharmaceuticals

Theranostics continue to gain momentum

by John R. Fischer , Staff Reporter
From the June 2019 issue of DOTmed HealthCare Business News magazine

In more ways than one, 2018 was a year of expansion for Novartis International. In January the company completed its $3.9 billion acquisition of nuclear medicine company Advanced Accelerator Applications (AAA), and in October it completed the $2.1 billion purchase of biopharmaceutical enterprise, Endocyte.

But in addition to scaling its company footprint, the Swiss-based pharmaceutical provider expanded its stake in another area — the emerging and promising field of theranostics. With AAA providing it access to its neuroendocrine tumor treatment, 177-Lu-Lutathera, and Endocyte giving it the same for its prostate cancer drug, 177-Lu-PSMA-617.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED

Interest in theranostics has driven a lot of business activity in recent years and energized not just companies but providers in nuclear medicine in working to develop radiotherapeutic molecules that can diagnose, determine a personalized course of action for, and treat various forms of cancer. The word itself is a portmanteau of diagnostics and therapeutics.

“The strong growth of radiotherapeutics represented around 14 percent of the total nuclear medicine market in 2018 - up from 3 percent in 2012 – and is expected to represent 60 percent, or even more, of the $26 billion U.S. nuclear medicine market by 2030,” Paul-Emmanuel Goethals, co-founder of MEDraysintell, a business intelligence firm specializing in nuclear medicine, told HCB News. “They are driving the growth of radiotheranostics, and their overall development along with that of conventional therapeutics will boost development of associated PET and SPECT tracers.”

Origins, and where it is today
Although the term was first coined in the 1990s, the concept of theranostics dates back to the 1940s when iodine was applied in both diagnostic imaging and therapy for benign and malignant thyroid tumors.

“You can give someone I-123, and using molecular imaging, you can see where the iodine goes and visualize metastatic thyroid cancer,” said Dr. Thomas Hope, a nuclear medicine physician and associate professor of radiology at the University of California, San Francisco. “Then, you can give them I-131, which has a different type of radiation emitted that can treat the thyroid cancer.”

This practice refers to a specific example of theranostics known as radiotheranostics. While in this scenario the same radionuclide is used for diagnosis and therapy, other forms of radiotheranostics involve different radionuclides paired together with a targeting ligand. One radionuclide is used to image the tumor, while the other is used to treat it.
  Pages: 1 - 2 - 3 - 4 >>

Molecular Imaging Homepage

You Must Be Logged In To Post A Comment

Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Gold Service Dealer Program
Receive RFP/PS
Healthcare Providers
See all
HCP Tools
A Job
Parts Hunter +EasyPay
Get Parts
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to, Inc. Copyright ©2001-2019, Inc.